Abstract: The present invention refers to a modulator, to be used for comprehensive multidimensional chromatography separations, to entrap and release sample solute fractions (entrapped in a capillary loop of fixed or variable volume), deriving from a capillary column with an internal diameter ranging from 0.01 mm to 0.53 mm, onto another capillary column with an internal diameter ranging from 0.01 mm to 0.53 mm. The micro-device has been integrated in a gas chromatographic system, composed of two ovens for the independent temperature control of the two columns; the micro-device is characterized, internally, by a system of channels that enable the controlled splitting of gas flow, entering the second capillary, to generate an optimum gas linear velocity and to release the pressure in excess, with the objective of attaining the maximum separation efficiency in the second column.

Abstract: An HPLC module utilizes a combination of compound-dedicated hardware providing line clearance between differing radiosynthesis and includes multiple compound-dedicated HPLC inject valves, each inject valve directing a fluid to a serially-connected HPLC column and UV flowcell so as to prevent cross-contamination between differing radiopharmaceutical syntheses. The module provides a disposable fluid path from each UV flowcell allowing for radioactive detection, fraction collection, formulation and final product dispensing. In this manner, a level of GMP compliance is achieved that is suitable for meeting the requirements of an MHRA approved site-license.

Abstract: Systems and methods for detecting and/or identifying target cells (e.g., bacteria) using engineered transduction particles are described herein. In some embodiments, a method includes mixing a quantity of transduction particles within a sample. The transduction particles are associated with a target cell. The transduction particles are non-replicative, and are engineered to include a nucleic acid molecule formulated to cause the target cell to produce a series of reporter molecules. The sample and the transduction particles are maintained to express the series of the reporter molecules when target cell is present in the sample. A signal associated with a quantity of the reporter molecules is received. In some embodiments, a magnitude of the signal is independent from a quantity of the transduction particle above a predetermined quantity.

Abstract: Novel phenyl-glyoxal based anti-citrulline probes and methods of synthesis are provided. Methods of use, such as, the development of methods for monitoring substrate citrullination over time; for identifying citrullinated proteins from cells are described.

Abstract: Provided is a method for detecting analyte in a sample, which method comprises: (a) contacting the sample with a peptide nucleic acid (PNA) probe; (b) performing an electrochemical impedance spectrometry (EIS) measurement on the sample; (c) determining the presence, absence, quantity and/or identity of the analyte from the EIS measurement; wherein the analyte comprises nucleic acid; and wherein the quantity of analyte in the sample when the sample is taken is substantially the same as the quantity of analyte in the sample when the sample is subjected to the EIS measurement.

Abstract: The present invention describes a method and devices for the simultaneous detection, recovery identification and counting of a plurality of microorganisms consisting in providing mixtures of nutrients specially selected from those that curtail the lag phase of growth in bacteria and moulds and which, together with fluorescent enzymatic, chromogenic or bioluminescent markers and other nutrient components or growth inhibitors, are embedded in three-dimensional structures or natural or artificial clays or ceramics with cavities of different dimensions and forms and specific surface areas of between 2×103 and 6×108 m2/m3.

Abstract: Quantitation of analytes, including but not limited to peptides, polypeptides, and proteins, in mass spectrometry using a labeled peptide coupled to a reporter, and a universal reporter.

Abstract: The present invention concerns embodiments for determining whether an individual in need of immunotherapy will be responsive to the immunotherapy. Determination of one or more SNPs in particular genes is predictive of responsiveness to immunotherapy, particularly in individuals that have melanoma, for example. In certain embodiments, the SNPs are in ITGB2, SP1 1O, ILIB, IL23R, SLC11A1, IL12B, CCR5, TNF, ILIO, CXCL12, BTNL2, ANKRD20A4, CD 14, P2X7, IL8, TLR2, and/or CD209.

Abstract: A self-contained, fully automated, biological assay-performing apparatus includes a housing; a dispensing platform including a controllably-movable reagent dispensing system, disposed in the housing; a reagent supply component disposed in the housing; a pneumatic manifold removably disposed in the housing in a space shared by the dispensing platform, removably coupled to a fluidic transport layer and a plurality of reservoirs, wherein the fluidic transport layer, the reservoirs, and a test sample to be introduced therein are disposed in the housing in the space separate from the dispensing platform; a pneumatic supply system removably coupled to the pneumatic manifold in the housing in a space separate from the dispensing platform; and a control system coupled to at least one of the dispensing platform and the pneumatic supply system, disposed in the housing.

Abstract: The present invention relates to a method for quantifying the relative content of a protein in a sample. The present invention also relates to a method for comprising the relative content of a protein in at least two samples.

Abstract: The present invention relates to mass spectrometry methods employing multiple reaction monitoring (MRM) in the field of cancer therapeutics, specifically prostate cancer and melanoma.

Abstract: The present disclosure relates to compositions and methods for detecting rare nucleic acid molecule mutations in a plurality of nucleic acid molecules. Also disclosed are methods for determining the size of a nucleic acid molecule using droplet digital PCR.

Abstract: A method for the diagnosis of prostate cancer, comprising the step of determining the presence or absence of at least three polypeptide markers in a sample, wherein the polypeptide marker is selected from markers 1 to 44 and 52 to 78 (frequency markers), or determining the amplitude of at least one polypeptide marker selected from markers 45 to 51 and 79 to 115 (amplitude markers), wherein said sample is a urine sample or seminal fluid sample.

Abstract: Methods for the detection and screening of hepatocellular carcinoma (HCC) patients and for the monitoring of HCC treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. In other aspects, methods for detection and screening for the progression of high-risk conditions, such as HCV infections, to HCC and to monitoring treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. The biomarkers are sensitive and specific for the detection of HCC, and can also be used to classify HCV infections that are regarded as precursors of HCC.

Abstract: A method for recognizing rejection after a kidney transplantation (NTx), comprising the step of determining the presence or absence of at least one polypeptide marker in a sample, wherein said polypeptide marker is selected from markers 1 to 242 (frequency markers), or determining the amplitude of at least one polypeptide marker selected from markers 243 to 767 (amplitude markers), which are characterized by the values for the molecular masses and migration times (CE time).

Abstract: A triple sensor structured for simultaneous measurement of glucose, oxygen, and pH. The sensor components are in thin film states such as sensing films or membranes, with a glucose probe associated with emission of radiation in the blue part of the spectrum, an oxygen probe associated with radiation in red portion of the spectrum, and a pH probe—with a green portion of the spectrum. The optical probes are chemically grafted or immobilized in a suitable polymer matrix, alleviating the leaching of the probes from the matrix, improving the thin film sensing stability, and enabling the repeatable use of the same sensing films.

Abstract: A method of identifying proteins present in human serum which are differentially expressed between normal individuals and patients known to have non-small cell lung cancers and asthma, as diagnosed by a physician. Human serum specimens from each population are digested with trypsin or any other suitable endoproteinase and analyzed using a liquid chromatography electrospray ionization mass spectrometer. Mass spectral data from each population is compared to determine proteins with expression intensities which are significantly differentially expressed between the normal, asthma, and lung cancer populations. Eleven proteins are found to have expression intensities which are significantly differentially expressed between the populations. Finally, the identities of the eleven proteins are obtained by comparing the mass spectral data with known databases having libraries of mass spectral data of known proteins.

Abstract: A method for quantifying metallothionein protein isomers is described herein. Such metallothionein isomer protein quantification is useful for detecting and monitoring disease. As illustrated herein, protein quantification is a more accurate measure of metallothionein induction than is mRNA quantification.

Abstract: A high-throughput corrosion testing mechanism was developed for metals in a variety of environments in controlled, multiplexed microenvironments. Many parallel experiments can be conducted with microbial and environmental variables independently manipulated to identify the key determinants of corrosion progression. The synthetic assay design enables subsequent surface characterization of select samples within the array. In as little as one day, diverse corrosive environments can be compared quantitatively.

Abstract: The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.

Abstract: A magnetic-assisted rapid aptamer selection (MARAS) protocol for screening DNA aptamer is proposed. The MARAS protocol is able to efficiently generate aptamers with high affinity and specificity. A rotating magnetic field or alternating magnetic field was used in combination with target-bound magnetic micro-particles or nanoparticles to select DNA aptamers having desirable affinity and specificity to the target.

Abstract: The document pertains to a method for the purification of a ternary mixture of dimeric antibodies of the type AA, AB, BB, characterized in that for the separation of the three components and in particular for the isolation of the multi-specific fraction AB multicolumn counter current solvent gradient purification chromatography with a stationary phase load of more than 1 mg antibody mixture per milliliter stationary phase is used. It furthermore relates to a method for the identification of in particular bispecific antibody systems, which are particularly suitable for the application of such a purification method.

Abstract: Indole-3-propionic acid as a marker and for treatment for Huntington Disease.

Abstract: Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.

Abstract: Described herein is a digital microfluidic droplet generator (DMDG) and a microfluidic platform for processing material introduced into the DMDG. The combination is particularly suited for hydrogen/deuterium exchange and mass spectrometer (HDX-MS) processing and analysis of membrane proteins.

Abstract: The current disclosure reveals a complex regulatory pattern between miR-31 and AR, indicating that miR-31 plays a key role in prostate cancer development and progression. Another aspect of the current disclosure shows that miR-31 directly targets and destabilizes AR mRNA through interaction with the AR mRNA coding sequence showing that miR-31, or a fragment thereof has the ability to act as a novel therapeutic agent in treating cancer. The current disclosure also shows that AR indirectly represses miR-31 expression by binding to the miR-31 promoter region and modulating methyltransferase activity. Another aspect of the current disclosure shows that miR-31 indirectly modulates AR activity by modulating regulators of cell cycle progression. The disclosure further provides an isolated nucleic acid that modulates the activity of the androgen receptor in a cell.

Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using hydroxy-sphingomyelin SM-OH-22:1 as biomarker.

Abstract: The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analysed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta/delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-M, apolipoprotein E, C4b-binding protein beta chain, intact/cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.

Abstract: A micro-fluidic device for mapping a DNA or RNA strand labeled at a plurality of specific sites with labels suitable for generating a detection signal when interacting with a detector element, the device comprising: a micro-fluidic channel; and a plurality of detector elements for detecting the labels by acquiring the detection signals, the detector elements being positioned longitudinally along the micro-fluidic channel, each detector element having a width, successive detector elements being separated by an inter-detector gap having a width, wherein the widths of at least two of the detector elements are different and/or wherein the widths at least two of the inter-detector gaps are different.

Abstract: It is intended to evaluate an ischemic heart disease with high accuracy by convenient operation. The method for evaluating an ischemic heart disease according to the present invention comprises the steps of: assaying complement factor H and/or complement factor D in a sample derived from the blood of a test subject; and comparing the concentration of the complement factor H and/or the concentration of the complement factor D assayed in the preceding step with a reference value(s), wherein it is determined that the seriousness of the ischemic heart disease is high when the concentration falls below the reference value.

Abstract: This document provides methods and materials for assessing metabolites in a sample from a mammal (e.g., human) for determining the nature and extent of colorectal cancer (CRC) metastasis. For example, the document relates to the diagnosis, staging and prognosis of CRC in a mammal.

Abstract: A method for characterizing the risk a subject will develop an autoimmune and/or alloimmune disease following tissue transplant includes obtaining a biological sample from the subject, wherein the subject has received the tissue transplant determining in the biological sample a level of at least one protein selected from Tables 1-4, comparing the measured level of the at least one protein to a control value, and characterizing a subject as at greater risk of developing an autoimmune disease and/or alloimmune disease if the level of at least one protein determined is increased or decreased compared to the control value.

Abstract: The presently disclosed subject matter provides methods using mass spectrometry for direct profiling of N-linked glycans from a biological sample. In addition, the embodiments of the present invention also disclose novel methods, known as targeted analyte detection (TAD), for improving the detection limit of MALDI-MS. These methods take advantage of the carrier effect of the added standard analytes, which occurs due to the generic sigmoidal shape of the calibration curve. The functionality of TAD depends on the relative enhancement of sensitivity over the increase of the standard deviation at the analysis of target analytes with spiking in exogenous concentration. At certain ranges of exogenous concentration, the increment in the sensitivity overcomes the standard deviation, resulting in an improved LOD. Theoretically, exogenous concentrations approximately at 1 LODorig would generate the optimum LOD improvement.

Abstract: The use of a tag moiety comprising a biotinylation domain, such as biotin carboxyl carrier protein (BCCP), as a protein folding marker and protein solubility enhancer in the orientated surface capture of products of heterologously expressed genes is described. Methods for increasing the solubility of proteins and determining the folded state of a protein are also disclosed. The uses and methods of the invention can be carried out in a multiplexed manner on more than one protein in the formation of libraries. In addition the nucleic acid molecule encoding the biotinylation domain of the tag moiety can be used to increase the proportion of clones in a library that express the protein of interest.

Abstract: This invention relates to a method for characterizing and/or determining a samples, particularly in the aid of lanthanide(III) ions and ligands including an aromatic structure and 2-5 chelating heteroatoms. The invention relates also to an array for characterizing and/or determining a samples utilizing the properties of lanthanide(III) chelates.

Abstract: The present invention generally pertains to methods and kits for managing the variation in spectroscopic intensity measurements through the use of a reference component. The reference component may comprise a reference spectroscopic substance and may be contained together with a sample of interest in a sample to be tested, wherein the sample of interest may comprise a sample spectroscopic substance. Each sample to be tested may be uniquely identified and, hence, “barcoded” by combinations of different colors and concentrations of spectroscopic substances, contained therein.

Abstract: The present invention provides a compound represented by the formula (I): or a salt thereof; and a method of quantitatively analyzing an amino group-containing target substance, including labeling a target substance in samples by using, as a labeling compound, two or more of such compounds having a mutually different mass due to isotope labeling, to confer a mass difference to the target substance between two or more samples, and the like.

Abstract: A method for the diagnosis of the probability of Alzheimer's disease in a subject patient comprising the step of determining the presence or absence of at least three polypeptide markers in a sample, wherein the at least three polypeptide markers are at least three different markers selected from markers 1 to 50 (frequency markers) and markers 51 to 279 (amplitude markers), wherein the diagnosis is based on a comparison and ranking of the frequency and/or amplitude of the at least three polypeptide markers to the same at least three polypeptide markers obtained from control subjects with and without Alzheimer's disease.

Abstract: Systems, methods, and apparatuses are provided for diagnosing auto-immune diseases such as systemic lupus erythematosus (SLE) based on the sizes, methylation levels, and/or genomic characteristics of circulating DNA molecules. Patients provide blood or other tissue samples containing cell-free nucleic molecules for analysis. Massively parallel and/or methylation-aware sequencing can be used to determine the sizes and methylation levels of individual DNA molecules and identify the number of molecules originating from different genomic regions.

Abstract: Methods are provided for identifying biomarker proteins that exhibit differential expression in subjects with a first lung condition versus healthy subjects or subjects with a second lung condition. Also provided are compositions comprising these biomarker proteins and methods of using these biomarker proteins or panels thereof to diagnose, classify, and monitor various lung conditions. The methods and compositions provided herein may be used to diagnose or classify a subject as having lung cancer or a non-cancerous condition, and to distinguish between different types of cancer (e.g., malignant versus benign, SCLC versus NSCLC).

Abstract: The present invention relates in general to the field of colorectal cancer detection, and more particularly, to plasma microRNAs for the detection of early colorectal cancer.

Abstract: The present invention is directed to methods for predicting a pregnant woman's risk of developing early-onset preeclampsia or late-onset preeclampsia. The methods are based on measuring one or more metabolites obtained from a pregnant woman's bodily fluid, such as blood or urine, which were found to be predictive of early-onset preeclampsia and late-onset preeclampsia.

Abstract: Apparatus, systems, and methods for detecting, screening and sampling of cells are disclosed.

Abstract: A method and evaluation kit are provided, in which a high-capacity urate transporter is identified to assist in the early treatment and prevention of urate transport-related disease and inflammation-related disease. The method can include a step for detecting variations in genes that encode ABCG2 protein. When a subject has an SNP of V12M, R113X, Q126X, Q141K, F2085, G268R, E334X, S441N, L447V, S486N, F506SfsX4, R575X, and/or C608X, it can be concluded that the subject has a factor that is capable of inducing urate transport failure, or a state or disease attributable to that failure. When a subject has an SNP of V12M, it can be concluded that, unlike the other SNPs, there is a possibility that the subject does not possess such a factor because, although this variation itself does not lead to a change in urate transport capability, said variation is related to linkage disequilibrium with other SNPs.

Abstract: The present invention is directed to methods for predicting a pregnant woman's risk of carrying a fetus with Down syndrome (Trisomy 21) or Trisomy 18. The methods are based on measuring one or more metabolites obtained from a pregnant woman's bodily fluid, such as blood or urine, and found to be predictive of Trisomy 21 or Trisomy 18.

Abstract: The invention generally relates to methods for isolating proteins. In certain aspects, methods of the invention involve preparing a plurality of sample preparations, each preparation including one or more intact cells. A capture unit is introduced to a plurality of the preparations. The capture unit includes a member that transiently interacts with one or more proteins in the cells and a reactive functional group. The sample preparations are incubated, and a reaction is initiated at a different time in a plurality of the preparation. In this manner, a protein within the cell that specifically interacts with the member of the capture unit becomes bound to the capture unit via the reactive functional group to form protein/capture unit complexes. The cells are lysed and the protein/capture unit complexes are isolated.

Abstract: The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 44:6 that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject.

Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using 9-oxo-HODE as biomarker.

Abstract: The present invention relates to the use of N-linked glycan profiles of blood or blood component proteins as biomarkers for diagnosing diabetes mellitus and for monitoring the efficacy of anti-diabetic therapy. Specifically, the present invention relates to detecting changes in the amounts of N-linked glycans as diagnostic biomarkers for diabetes mellitus and as indicators of the efficacy of anti-diabetic therapy over time.

Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins that are particularly advantageous for quantifying the KRT5, KRT7, NapsinA, TTF1, TP63, and/or MUC1 proteins directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.